14 results about "CD64" patented technology

A method of treating male hypogonadism in a subject in need thereof includes administering to the subject testicular organoids generated from isolated male progenitor cells. The method can be used to slow or halt the progression of age-related diseases, and increase healthspan and longevity, in hypogonadal males. The method can be used with subjects that have not or are not receiving testosterone replacement therapy. The method does not require that the subject is pre-treated with CG. The testicular organoid includes cells expressing GFRA1, VEGF, VEGFR2, PDGF-Rα, Cyp11A1, 3β-HSD, 17β-HSD, LHCGR, α-SMA, CD11b, MHC CII, CD64, CD95, Sox9, AR, inhibin β-B, and FSHR.

Described herein are novel vaccine compositions and methods for use thereof in inducing an immune response in a subject especially aged subjects. Specifically exemplified are vaccine compositions that include an antigen; a cyclic dinucleotide; soluble tumor necrosis factor (TNF); or a CD64 antibody or antibody fragment. Optionally, the vaccine composition comprises a TNF conjugated with a moDC targeting moiety in addition to or in place of TNF or CD64 antibody or antibody fragment, or both TNF and CD64 antibody or antibody fragment.

The invention provides an antibody composition for detecting immature mononuclear cells and application thereof, the antibody composition for detecting the immature mononuclear cells comprises a first group of antibodies and a second group of antibodies, the first group of antibodies comprises a CD15 antibody, a CD117 antibody, a CD34 antibody, a CD33 antibody, a CD14 antibody, an HLA-DR antibody, a CD13 antibody, a CD38 antibody, a CD64 antibody, a CD19 antibody, a CD56 antibody, a CD7 antibody and a CD45 antibody; and the second group of antibodies comprise an HLA-DR antibody, a CD64 antibody, a CD33 antibody, a CD14 antibody, a CD65 antibody and a CD45 antibody. According to the present invention, the flow cytometry is adopted to detect, and the antibody composition of the first group of antibodies and the second group of antibodies is provided, such that the detection sensitivity and the specificity are improved.

The application relates to the technical field of medical detection, in particular to a kit, a method and a system for predicting bacterial infection. The application provides a kit for predicting bacterial infection, which comprises an antibody combination for specifically recognizing CD64, CD14 and CD14, and the antibodies are respectively labeled with mutually distinguishable fluorescent dyes. Meanwhile, the application provides a method for predicting bacterial infection, which comprises obtaining the counts of neutrophils, lymphocytes and monocytes in a to-be-detected sample, and the fluorescent intensities of CD64 and CD14 on the cell subgroups, and calculating four characteristic parameters IDXNLR, IDXLMR, IDXCD64 and IDXCD14; and then inputting the parameters into a pre-trained infection diagnosis model to output a risk score for judging the infection state (especially bacterial infection). The model significantly improves the accuracy and specificity of distinguishing bacterial infection from non-bacterial infection (such as viral infection or healthy state) by comprehensively integrating immune parameters in multiple dimensions.

A recombinant immune cell expresses a heterologous IgG Fc receptor. In some embodiments, the heterologous IgG Fc receptor can be a chimeric IgG Fc receptor. Generally, the chimeric IgG Fc receptor includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain generally includes a sufficient portion of CD64 to bind to an IgG Fc region. The intracellular domain of the chimeric IgG Fc receptor includes a sufficient portion of an Fc receptor allowing immunoreceptor tyrosine-based activation motif (ITAM) to initiate cell signaling when an IgG Fc region binds to the extracellular domain.

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a U937 cell modified to express one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. Further provided are lipid nanoparticles (LNPs) conjugated to one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs or LNPs and methods of treating cancers using TILs after expansion with aAPCs or LNPs are also disclosed.

The application discloses a nucleic acid aptamer capable of recognizing and combining with CD64 protein and application thereof. The application provides various nucleic acid aptamers and mutants thereof. The nucleic acid aptamer has high affinity, is non-immunogenic, can be chemically synthesized in vitro, has small molecular weight, can be modified and replaced at different positions, is stable in sequence, easy to preserve, convenient to label (without a secondary antibody), and the like. When the nucleic acid aptamer is used for detecting CD64 protein, the operation is simple and rapid, the affinity is high, the synthesis cost of the nucleic acid aptamer is lower than that of an antibody, the period is short, and the reproducibility is good. The application can be used in many fields such as disease diagnosis and treatment, drug screening, molecular recognition and analysis detection, and the like.

Provided herein are, inter alia, polypeptides and covalent complexes including the same, with multivalent binding specificity. The polypeptides include an Fc receptor portion / domain (e.g., a CD16 domain, a CD32 domain, a CD64 domain and variants thereof) with a cysteine amino acid substitution capapble of forming a disulfide linkeage with a second cysteine amino acid substitution in an Fc domain (e.g., an Fc domain of IgG1, IgG2, IgG3, IgG4) thereby forming a covalent complex with multivalent binding ability. The compositions provided herein exhibit highly specific binding with reduced or no endogenous Fc receptor binding activity thereby resulting in therapeutics that lack undesirable side effects.

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a U937 cell modified to express one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. Further provided are lipid nanoparticles (LNPs) conjugated to one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs or LNPs and methods of treating cancers using TILs after expansion with aAPCs or LNPs are also disclosed.

Provided is a recombinant Fc receptor and cells including same, and has cleavage resistance to ADAM17 through amino acid modification of an ADAM17 cleavage site in a CD16 polypeptide, and can improve binding affinity to an antibody Fc region by being substituted for all or a part of the extracellular binding domain of CD64.

The invention provides application of a combination of A beta1-42 and CD64 in preparation of a reagent for early detection of sepsis, and belongs to the technical field of biology, the diagnosis value of combined detection of A beta1-42 and CD64 is significantly higher than that of a single index, a synergistic effect is generated, and the technical problem that a single marker is insufficient in sensitivity or specificity is solved. The CD64 is quick in response, the Abeta1-42 is closely associated with the pathological process, and the combination is beneficial to identifying high-risk patients in the early stage of diseases and striving for precious intervention time for clinic. The marker combination not only can be used for qualitative diagnosis, but also can be used for risk stratification and prognosis judgment, and has comprehensive functions, and the quantification level of the marker combination is positively correlated with the severity of diseases.

This invention relates to an antibody composition for detecting PNH clones and its application. The antibody composition comprises a first antibody group, a second antibody group, and a third antibody group. The first antibody group includes a CD235a antibody, the second antibody group includes a CD235a antibody and a CD59 antibody, and the third antibody group includes a FLAER antibody, a CD157 antibody, a CD15 antibody, a CD64 antibody, and a CD45 antibody. In this invention, the three antibody groups can be used to identify mature erythrocytes, neutrophils, and monocytes in peripheral blood. PNH clones in erythrocytes are detected using CD235a and CD59, and PNH clones in neutrophils and monocytes are detected using FLAER and CD157 antibodies. The FLAER antibody directly binds to the GPI anchor structure, and the CD157 antibody, as an additional GPI anchor protein indicator, can detect potentially missed microclones.

Described herein are novel vaccine compositions and methods for use thereof in inducing an immune response in a subject especially aged subjects. Specifically exemplified are vaccine compositions that include an antigen; a cyclic dinucleotide; soluble tumor necrosis factor (TNF); or a CD64 antibody or antibody fragment. Optionally, the vaccine composition comprises a TNF conjugated with a moDC targeting moiety in addition to or in place of TNF or CD64 antibody or antibody fragment, or both TNF and CD64 antibody or antibody fragment.

The invention provides, for the first time, cells that comprise enhanced CD16, CD32, or CD64 expression to evade antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). The cells may be pluripotent cells, including hypoimmune pluripotent cells (HIP) or ABO blood type O Rhesus Factor negative HIP cells (HIPO-), that further comprise the enhanced CD16, CD32, or CD64 expression. The invention encompasses cells derived from the pluripotent cells.